Total Funding
1
Total FundingSeries D raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
470099
Presidio Pharmaceuticals discovers, develops and commercializes novel therapeutics for viral infections, including HCV and HIV.
Acquired by 
BioCryst Pharmaceuticals
Leping Li: Sr. DirectorPast Role: Chinese American BioPharmaceutical Society, President
Nathaniel Brown: Chief Medical Officer and Sr VP, Clinical DevelopmentPast Role: GlaxoWellcome, Director, Clinical & Scientific Affairs - Hepattis
About the Company
Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for viral infections, including HCV and HIV. Presidio has raised over $27 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, Nexus
Medical Partners, and Sagamore Bioventures LLC.
